Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
ARA-290 (cibinetide) for neuropathy: the clinical trial peptide If BPC-157 represents the strongest preclinical evidence for peptide-based nerve repair, ARA-290 represents the strongest clinical evidence
10.1186/s12967-024-04853-0 217
Seaver, L.C
Chronic sleep insufficiency and rhythm disruption in the elderly can exacerbate metabolic syndrome (hypertension, insulin resistance, dyslipidemia) and promote neuropsychiatric problems (Panagiotou et al., 2021
Future efforts will likely focus on optimizing treatment regimens, developing more specific interventions, and translating preclinical findings into clinical applications
Warburg O, Wind F, Negelein E
